Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.

CHB HCC PAGE-B score Sub-Sahara Africa Suriname advanced fibrosis modified PAGE-B score surveillance

Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
26 Oct 2023
Historique:
received: 08 06 2023
revised: 20 09 2023
accepted: 16 10 2023
pubmed: 29 10 2023
medline: 29 10 2023
entrez: 28 10 2023
Statut: aheadofprint

Résumé

Sub-Saharan African (SSA) ethnicity has been associated with a higher risk of hepatocellular carcinoma (HCC) among individuals with chronic hepatitis B in cross-sectional studies. However, the incidence of HCC and performance of HCC risk scores in this population are unknown. We conducted an international multicenter retrospective cohort study of all consecutive HBV-monoinfected individuals of SSA or Afro-Surinamese (AS) ethnicity managed at sites in the Netherlands, the United Kingdom and Spain. We assessed the 5- and 10-year cumulative incidences of HCC in the overall study population, among different clinically relevant subgroups and across (m)PAGE-B subgroups. Next, we explored the different risk factors for HCC. During a median follow-up of 8 years, we analyzed 1,473 individuals of whom 34 developed HCC. The 5- and 10-year cumulative incidences of HCC were 1% and 2.4%. The 10-year cumulative incidence of HCC was 0.7% among individuals without advanced fibrosis at baseline, compared to 12.1% among individuals with advanced fibrosis (p <0.001). Higher age (adjusted hazard ratio [aHR] 1.05), lower platelet count (aHR 0.98), lower albumin level (aHR 0.90) and higher HBV DNA log10 (aHR 1.21) were significantly associated with HCC development. The 10-year cumulative incidence of HCC was 0.5% among individuals with a low PAGE-B score, compared to 2.9% in the intermediate- and 15.9% in the high-risk groups (p <0.001). In this unique international multicenter cohort of SSA and AS individuals with chronic hepatitis B, we observed 5- and 10-year cumulative HCC risks of 1% and 2.4%, respectively. The risk of HCC was negligible for individuals without advanced fibrosis at baseline, and among individuals with low baseline (m)PAGE-B scores. These findings can be used to guide HCC surveillance strategies. Sub-Saharan African ethnicity has been associated with a higher risk of hepatocellular carcinoma among individuals with chronic hepatitis B. In this international multicenter cohort study of sub-Saharan African and Afro-Surinamese individuals living with chronic hepatitis B in Europe, we observed 5- and 10-year cumulative incidences of hepatocellular carcinoma of 1% and 2.4%, respectively. The risk was negligible among individuals without advanced fibrosis and a low baseline (m)PAGE-B score. These findings can be used to guide HCC surveillance strategies in this population.

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
Sub-Saharan African (SSA) ethnicity has been associated with a higher risk of hepatocellular carcinoma (HCC) among individuals with chronic hepatitis B in cross-sectional studies. However, the incidence of HCC and performance of HCC risk scores in this population are unknown.
METHODS METHODS
We conducted an international multicenter retrospective cohort study of all consecutive HBV-monoinfected individuals of SSA or Afro-Surinamese (AS) ethnicity managed at sites in the Netherlands, the United Kingdom and Spain. We assessed the 5- and 10-year cumulative incidences of HCC in the overall study population, among different clinically relevant subgroups and across (m)PAGE-B subgroups. Next, we explored the different risk factors for HCC.
RESULTS RESULTS
During a median follow-up of 8 years, we analyzed 1,473 individuals of whom 34 developed HCC. The 5- and 10-year cumulative incidences of HCC were 1% and 2.4%. The 10-year cumulative incidence of HCC was 0.7% among individuals without advanced fibrosis at baseline, compared to 12.1% among individuals with advanced fibrosis (p <0.001). Higher age (adjusted hazard ratio [aHR] 1.05), lower platelet count (aHR 0.98), lower albumin level (aHR 0.90) and higher HBV DNA log10 (aHR 1.21) were significantly associated with HCC development. The 10-year cumulative incidence of HCC was 0.5% among individuals with a low PAGE-B score, compared to 2.9% in the intermediate- and 15.9% in the high-risk groups (p <0.001).
CONCLUSIONS CONCLUSIONS
In this unique international multicenter cohort of SSA and AS individuals with chronic hepatitis B, we observed 5- and 10-year cumulative HCC risks of 1% and 2.4%, respectively. The risk of HCC was negligible for individuals without advanced fibrosis at baseline, and among individuals with low baseline (m)PAGE-B scores. These findings can be used to guide HCC surveillance strategies.
IMPACT AND IMPLICATIONS UNASSIGNED
Sub-Saharan African ethnicity has been associated with a higher risk of hepatocellular carcinoma among individuals with chronic hepatitis B. In this international multicenter cohort study of sub-Saharan African and Afro-Surinamese individuals living with chronic hepatitis B in Europe, we observed 5- and 10-year cumulative incidences of hepatocellular carcinoma of 1% and 2.4%, respectively. The risk was negligible among individuals without advanced fibrosis and a low baseline (m)PAGE-B score. These findings can be used to guide HCC surveillance strategies in this population.

Identifiants

pubmed: 37898348
pii: S0168-8278(23)05219-4
doi: 10.1016/j.jhep.2023.10.019
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Lesley A Patmore (LA)

Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. Electronic address: l.patmore@erasmusmc.nl.

Kirsi M A van Eekhout (KMA)

Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Maria Buti (M)

Liver Unit, Hospital University Valle d'Hebron, Barcelona, Spain.

Özgur M Koc (ÖM)

Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.

Kosh Agarwal (K)

Institute of Liver Studies, King's College Hospital, London, United Kingdom.

Rob J de Knegt (RJ)

Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Harry L A Janssen (HLA)

Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto, Toronto, Canada.

Marc van der Valk (M)

Amsterdam University Medical Centers, University of Amsterdam, Department of Infectious Disease, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands; Hiv Monitoring Foundation, Amsterdam, The Netherlands.

Faydra I Lieveld (FI)

Department of Gastroenterology and Hepatology, Utrecht UMC, Utrecht, The Netherlands; Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.

Bettina E Hansen (BE)

Deperatment of Epidemiology & Biostatistics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; IHPME, University of Toronto & Toronto Centre for Liver disease, UHN, Toronto, Canada.

Matthijs Kramer (M)

Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.

Joep de Bruijne (J)

Department of Gastroenterology and Hepatology, Utrecht UMC, Utrecht, The Netherlands.

Mark A A Claassen (MAA)

Department of Internal Medicine and Infectious Diseases, Rijnstate Hospital, Arnhem, The Netherlands.

Colette Smit (C)

Hiv Monitoring Foundation, Amsterdam, The Netherlands.

Rob A de Man (RA)

Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Bart Takkenberg (B)

Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Ivana Carey (I)

Institute of Liver Studies, King's College Hospital, London, United Kingdom.

Milan J Sonneveld (MJ)

Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Classifications MeSH